ES434687A1 - Procedimiento para preparar productos intermedios tetrahi- dropiranilicos de prostaglandinas. - Google Patents

Procedimiento para preparar productos intermedios tetrahi- dropiranilicos de prostaglandinas.

Info

Publication number
ES434687A1
ES434687A1 ES434687A ES434687A ES434687A1 ES 434687 A1 ES434687 A1 ES 434687A1 ES 434687 A ES434687 A ES 434687A ES 434687 A ES434687 A ES 434687A ES 434687 A1 ES434687 A1 ES 434687A1
Authority
ES
Spain
Prior art keywords
see formula
beta
alpha
integer
prostaglandins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES434687A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of ES434687A1 publication Critical patent/ES434687A1/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10Oxygen atoms
    • C07D309/12Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D317/00Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/54Radicals substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/54Quaternary phosphonium compounds
    • C07F9/5407Acyclic saturated phosphonium compounds

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
ES434687A 1972-11-08 1975-02-13 Procedimiento para preparar productos intermedios tetrahi- dropiranilicos de prostaglandinas. Expired ES434687A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30481572A 1972-11-08 1972-11-08

Publications (1)

Publication Number Publication Date
ES434687A1 true ES434687A1 (es) 1976-12-16

Family

ID=23178143

Family Applications (2)

Application Number Title Priority Date Filing Date
ES420326A Expired ES420326A1 (es) 1972-11-08 1973-11-07 Un procedimiento para preparar esteres p-bifenilicos de o- mega-pentanorprostaglandinas sustituidas en la posicion 15.
ES434687A Expired ES434687A1 (es) 1972-11-08 1975-02-13 Procedimiento para preparar productos intermedios tetrahi- dropiranilicos de prostaglandinas.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES420326A Expired ES420326A1 (es) 1972-11-08 1973-11-07 Un procedimiento para preparar esteres p-bifenilicos de o- mega-pentanorprostaglandinas sustituidas en la posicion 15.

Country Status (24)

Country Link
JP (1) JPS5644068B2 (es)
AR (2) AR204816A1 (es)
AT (1) AT347607B (es)
BE (1) BE807047A (es)
CA (1) CA1027559A (es)
CH (1) CH601222A5 (es)
CS (1) CS188175B2 (es)
DD (2) DD111370A5 (es)
DE (2) DE2365999A1 (es)
ES (2) ES420326A1 (es)
FI (1) FI58116C (es)
FR (2) FR2205339B1 (es)
GB (1) GB1456511A (es)
HU (2) HU171818B (es)
IE (1) IE39686B1 (es)
IL (1) IL43553A (es)
IN (1) IN139905B (es)
NL (1) NL7315240A (es)
NO (2) NO145437C (es)
PH (2) PH15504A (es)
SE (2) SE420198B (es)
SU (2) SU538659A3 (es)
YU (2) YU287973A (es)
ZA (1) ZA738593B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2361381A1 (fr) * 1972-07-13 1978-03-10 Pfizer Ethers tetrahydropyranyliques, utiles comme intermediaires de synthese de prostaglandines
US3929862A (en) * 1974-01-08 1975-12-30 Upjohn Co Substituted tolylesters of PGF{HD 2{B {60
US3998869A (en) * 1974-11-14 1976-12-21 The Upjohn Company Substituted anilide esters of 16-substituted PGE2
DE2737807A1 (de) * 1976-08-27 1978-03-09 Pfizer C tief 1 -p-biphenylester von omega-pentanorprostaglandinen
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure

Also Published As

Publication number Publication date
NO146280C (no) 1982-09-01
JPS49100060A (es) 1974-09-20
JPS5644068B2 (es) 1981-10-16
NO145437C (no) 1982-03-24
AR202311A1 (es) 1975-05-30
SE420198B (sv) 1981-09-21
CH601222A5 (es) 1978-06-30
HU171945B (hu) 1978-04-28
DE2355042A1 (de) 1974-05-22
PH13794A (en) 1980-10-01
NL7315240A (es) 1974-05-10
FR2275452A1 (fr) 1976-01-16
FR2275452B1 (es) 1977-12-16
CS188175B2 (en) 1979-02-28
HU171818B (hu) 1978-03-28
IN139905B (es) 1976-08-14
IE39686L (en) 1974-05-08
NO146280B (no) 1982-05-24
FR2205339A1 (es) 1974-05-31
CA1027559A (en) 1978-03-07
DD111370A5 (es) 1975-02-12
ATA937173A (de) 1978-05-15
IE39686B1 (en) 1978-12-06
AT347607B (de) 1979-01-10
DE2365999A1 (de) 1977-05-12
PH15504A (en) 1983-02-03
FI58116B (fi) 1980-08-29
NO743588L (no) 1974-05-09
FI58116C (fi) 1980-12-10
IL43553A0 (en) 1974-03-14
SE7704369L (sv) 1977-04-15
FR2205339B1 (es) 1980-01-04
YU287973A (en) 1982-02-25
IL43553A (en) 1979-10-31
SU538659A3 (ru) 1976-12-05
DD113211A5 (es) 1975-05-20
AR204816A1 (es) 1976-03-05
ZA738593B (en) 1974-10-30
NO145437B (no) 1981-12-14
SU1021340A3 (ru) 1983-05-30
GB1456511A (en) 1976-11-24
ES420326A1 (es) 1976-03-16
YU264480A (en) 1983-04-27
BE807047A (fr) 1974-05-08
AU6222573A (en) 1975-05-08

Similar Documents

Publication Publication Date Title
US4107214A (en) 2-Decarboxy-2-hydroxy-methyl-3,7-inter-m-phenylene-ω-phenoxy-PGD.sub.1
ES433046A1 (es) Un procedimiento para preparar productos intermedios de prostaglandinas.
ES434687A1 (es) Procedimiento para preparar productos intermedios tetrahi- dropiranilicos de prostaglandinas.
ES437038A1 (es) Procedimiento para preparar dialquil-fosfonatos.
ES471349A1 (es) Un procedimiento para la preparacion de un compuesto de pi- rrolidona
US4068083A (en) 2,2-Difluoro-13,14-dihydro-PGE1 analogs
ES395380A1 (es) Un procedimiento para la produccion de un compuesto de car-bamato.
ES402263A1 (es) Un metodo para sintetizar nuevos analogos de prostaglandi- na.
US4065631A (en) 17-Phenyl-18,19,20-trinor-cis-4,5-didehydro-PGF1β compounds
US4151359A (en) 11-Deoxy-17-phenyl-13,14-dihydro-PGE2 compounds
SE7407100L (es)
ES462784A1 (es) Procedimiento para la produccion de cromanonas.
ES441003A1 (es) Un procedimiento para preparar productos intermedios utiles en la sintesis de prosglandinas.
US4056554A (en) 2,2-Difluoro-16-phenoxy-13,14-dihydro-PGF1, analogs
US4059614A (en) 2,2-Difluoro-16-phenoxy-PGE1 analogs
US4055563A (en) Cyano intermediates for prostaglandins
ES417557A1 (es) Un procedimiento para preparar derivados de ciclopentano sustituido.
US4056556A (en) 2,2-Difluoro-16-phenoxy-PGE2 analogs
ES430417A1 (es) Procedimiento para preparar bromuro de amidoalquil-trifenil-fosfonio.
ES425868A1 (es) Procedimiento para la preparacion de n-alquilcarbonatos fenil-substituidos.
ES423013A1 (es) Un procedimiento para la preparacion de 5-bromo-5-nitro-2- alquil-1,3-dioxanos.
ES285360A1 (es) Procedimiento para la preparación de compuestos tricíclicos
GB1446344A (en) Bis-tetrahydropyranyl-ethers
ES377775A1 (es) Procedimiento para la obtencion del ester bis-(n-meticarba-mico) del 2,6-piridindimetanol.
JPS5225785A (en) Preparation of 2-substituted-4- trichloromethyl-6-trifluoromethyl-s- t riazines